- Investing Ideas
- /
- Software Healthcare Sector
Software Healthcare Sector
Results
2311
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
2,311 companies
Arcus Biosciences
Market Cap: US$876.7m
A clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
RCUS
US$8.28
7D
-9.2%
1Y
-50.4%
Ardelyx
Market Cap: US$866.1m
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$3.62
7D
-12.3%
1Y
-53.4%
Extendicare
Market Cap: CA$1.2b
Through its subsidiaries, provides care and services for seniors in Canada.
EXE
CA$14.33
7D
-1.2%
1Y
86.6%
CareDx
Market Cap: US$855.3m
Engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally.
CDNA
US$15.36
7D
2.4%
1Y
3.6%
Spyre Therapeutics
Market Cap: US$851.0m
A clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD).
SYRE
US$14.10
7D
-6.7%
1Y
-61.8%
HealthStream
Market Cap: US$849.8m
Provides Software-as-a-Service (SaaS) based applications for healthcare organizations in the United States.
HSTM
US$27.84
7D
-18.3%
1Y
4.0%
Intellia Therapeutics
Market Cap: US$841.1m
A clinical-stage gene editing company, focuses on the development of curative genome editing treatments.
NTLA
US$8.12
7D
-8.1%
1Y
-66.8%
AMN Healthcare Services
Market Cap: US$840.4m
Provides technology-enabled healthcare workforce solutions and staffing services to acute and sub-acute care hospitals, and other healthcare facilities in the United States.
AMN
US$22.00
7D
3.6%
1Y
-59.8%
Gyre Therapeutics
Market Cap: US$839.6m
A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
GYRE
US$9.53
7D
2.9%
1Y
-35.7%
Liminatus Pharma
Market Cap: US$836.1m
Liminatus Pharma, LLC operates as a clinical-stage immuno-oncology company that develops novel cancer therapies.
LIMN
US$7.45
7D
-7.3%
1Y
-29.1%
Craneware
Market Cap: UK£626.8m
Develops, licenses, and supports computer software for the healthcare industry in the United States.
CRW
UK£17.90
7D
-3.8%
1Y
-20.1%
Trulieve Cannabis
Market Cap: CA$1.2b
Operates as a cannabis retailer.
TRUL
CA$6.06
7D
-5.9%
1Y
-61.8%
Xeris Biopharma Holdings
Market Cap: US$802.4m
A commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.
XERS
US$5.01
7D
6.4%
1Y
184.7%
CorMedix
Market Cap: US$790.8m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$11.66
7D
24.3%
1Y
125.5%
SI-BONE
Market Cap: US$787.9m
A medical device company, focuses on solving musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally.
SIBN
US$18.49
7D
32.2%
1Y
20.6%
Zymeworks
Market Cap: US$787.8m
A clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID).
ZYME
US$11.31
7D
-12.8%
1Y
28.3%
CureVac
Market Cap: US$781.3m
A biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
CVAC
US$3.47
7D
-2.5%
1Y
19.2%
Praxis Precision Medicines
Market Cap: US$781.2m
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance.
PRAX
US$38.35
7D
-4.7%
1Y
-21.4%
Cronos Group
Market Cap: CA$1.1b
A cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally.
CRON
CA$2.76
7D
8.2%
1Y
-27.4%
Rocket Pharmaceuticals
Market Cap: US$753.1m
Operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States.
RCKT
US$6.99
7D
-12.7%
1Y
-69.2%
Geron
Market Cap: US$751.6m
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
GERN
US$1.18
7D
-14.5%
1Y
-68.9%
LENZ Therapeutics
Market Cap: US$741.4m
Operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.
LENZ
US$26.34
7D
-10.8%
1Y
67.5%
Veradigm
Market Cap: US$729.6m
A healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally.
MDRX
US$4.30
7D
-2.3%
1Y
-44.8%
Nurix Therapeutics
Market Cap: US$724.2m
A clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
NRIX
US$9.50
7D
-15.7%
1Y
-29.7%
WELL Health Technologies
Market Cap: CA$991.4m
Operates as a practitioner-focused digital healthcare company in Canada, the United States, and internationally.
WELL
CA$3.92
7D
-0.8%
1Y
0%
Nuvation Bio
Market Cap: US$711.1m
A clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology.
NUVB
US$2.09
7D
-15.0%
1Y
-35.7%
Bicara Therapeutics
Market Cap: US$707.3m
A clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.
BCAX
US$12.97
7D
-10.6%
1Y
n/a
Niagen Bioscience
Market Cap: US$706.5m
Operates as a bioscience company engages in developing healthy aging products.
NAGE
US$8.95
7D
11.9%
1Y
161.7%
Anavex Life Sciences
Market Cap: US$704.3m
A clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States.
AVXL
US$8.25
7D
-11.9%
1Y
116.5%
Vir Biotechnology
Market Cap: US$702.9m
A clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
VIR
US$5.09
7D
-17.5%
1Y
-46.1%
uniQure
Market Cap: US$700.0m
Develops treatments for patients suffering from rare and other devastating diseases in the United States.
QURE
US$12.79
7D
-13.4%
1Y
160.0%
Embecta
Market Cap: US$698.2m
A medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes in the United States and internationally.
EMBC
US$11.97
7D
-6.0%
1Y
-15.9%
ArriVent BioPharma
Market Cap: US$686.0m
A clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.
AVBP
US$20.15
7D
-5.4%
1Y
13.8%
Mesa Laboratories
Market Cap: US$672.9m
Develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally.
MLAB
US$123.84
7D
4.0%
1Y
6.7%
Trevi Therapeutics
Market Cap: US$671.5m
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough conditions targeting the central and peripheral nervous systems.
TRVI
US$6.60
7D
-5.6%
1Y
141.8%
Akebia Therapeutics
Market Cap: US$669.7m
A biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
AKBA
US$2.55
7D
4.1%
1Y
110.7%